We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+24.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$498M
AUM Growth
+$258M
Cap. Flow
+$49.1M
Cap. Flow %
9.86%
Top 10 Hldgs %
69.52%
Holding
145
New
57
Increased
20
Reduced
22
Closed
41

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$31.2M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$6.99M
3
MRNA icon
Moderna
MRNA
+$3.94M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$3.78M
5
MTVA
MetaVia Inc
MTVA
+$3.18M

Top Sells

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$2.89M
2
ENLV icon
Enlivex Ltd
ENLV
+$2.31M
3
NOVN
Novan, Inc. Common Stock
NOVN
+$2.11M
4
OTLK icon
Outlook Therapeutics
OTLK
+$1.94M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 11.32%
2 Industrials 0.26%
3 Technology 0.12%
4 Consumer Discretionary 0.09%
5 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALT icon
26
PUT
Altimmune
ALT
$581M
$3.06M 0.61%
2,859
+2,325
+435% +$12.8K
CVM.WS
27
CALL
DELISTED
Cel-Sci Corp Series S
CVM.WS
$2.92M 0.59%
+1,959
New +$2.92M
XERS icon
28
Xeris Biopharma Holdings
XERS
$1.42B
$2.89M 0.58%
+1,086,031
New +$3.78M
PLLL
29
DELISTED
Piedmont Lithium Limited American Depositary Receipts
PLLL
$2.88M 0.58%
+498,259
New +$2.88M
CRIS icon
30
Curis
CRIS
$9.41M
$2.74M 0.55%
+5,668
New +$2.09M
ALNA
31
DELISTED
Allena Pharmaceuticals
ALNA
$2.42M 0.49%
+1,531,446
New +$2.57M
NKLA
32
PUT
DELISTED
Nikola Corporation Common Stock
NKLA
$2.33M 0.47%
+12
New +$11.6K
AVEO
33
CALL
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.19M 0.44%
4,255
+26
+0.6% +$164
ODT
34
PUT
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$2.01M 0.4%
475
+30
+7% +$971
MTVA
35
MetaVia Inc
MTVA
$7.39M
$1.87M 0.38%
+88
New +$3.18M
TRIL
36
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.84M 0.37%
2,275
+1,275
+128% +$7.89K
ODT
37
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$1.72M 0.34%
40,500
-8,488
-17% -$275K
AZN icon
38
AstraZeneca
AZN
$267B
$1.66M 0.33%
+15,660
New +$1.62M
KYNB
39
Kyntra Bio
KYNB
$28.2M
$1.36M 0.27%
+1,342
New +$1.25M
CVM icon
40
CEL-SCI Corp
CVM
$21M
$1.32M 0.26%
2,947
+1,112
+61% +$457K
GLBS icon
41
Globus Maritime Ltd
GLBS
$60.9M
$1.27M 0.26%
+47,767
New +$3.03M
IBB icon
42
iShares Biotechnology ETF
IBB
$9.55B
$1.25M 0.25%
+9,130
New +$1.16M
NKLAW
43
DELISTED
Nikola Corporation Warrant expiring 6/3/2025
NKLAW
$1.15M 0.23%
+34,500
New +$985K
CLDX icon
44
CALL
Celldex Therapeutics
CLDX
$2.79B
$1.02M 0.2%
+782
New +$3.47K
MRNA icon
45
CALL
Moderna
MRNA
$22.1B
$1.01M 0.2%
+158
New +$8.65K
IONS icon
46
PUT
Ionis Pharmaceuticals
IONS
$9.14B
$991K 0.2%
+168
New +$9.35K
CLDX icon
47
Celldex Therapeutics
CLDX
$2.79B
$950K 0.19%
+73,094
New +$324K
ODT
48
CALL
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$944K 0.19%
+223
New +$7.22K
SCPH
49
DELISTED
scPharmaceuticals
SCPH
$926K 0.19%
+125,752
New +$1.1M
PAVMZ
50
DELISTED
PAVmed Inc. Series Z Warrant
PAVMZ
$867K 0.17%
842,210
-193,186
-19% -$213K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sabby Management held 145 positions worth $498M, up 107% from $241M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management deployed $49.1M of net new capital in Q2 2020, opening 57 new positions and adding to 20 existing holdings. Its largest new stake was Biogen: 103,902 shares worth $27.8M.

By sector, the portfolio is most concentrated in Healthcare at 11% of assets, up from 7.3% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Enlivex Ltd, an estimated $2.31M trimmed.

  • Sabby Management's largest Q2 2020 buy was Biogen: 103,902 shares worth $27.8M.
  • Sabby Management added most to State Street Health Care Select Sector SPDR ETF in Q2 2020, an estimated $6.99M increase.
  • Sabby Management's biggest Q2 2020 reduction was Enlivex Ltd, cutting an estimated $2.31M.
  • Sabby Management fully exited SPDR Gold Trust in Q2 2020, selling an estimated $2.89M.
  • Sabby Management's ten largest holdings make up 70% of its $498M portfolio in Q2 2020.
  • Sabby Management opened 57 new positions and closed 41 in Q2 2020.
  • Sabby Management's portfolio value rose 107% quarter-over-quarter to $498M.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.